Compare Bristol-Myers Squibb Co (BMY) vs Coinbase Global, Inc. (COIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Coinbase Global, Inc. — how do they compare? Bristol-Myers Squibb Co trades at $63.7 (market cap $129.94B), while Coinbase Global, Inc. trades at $149.4 (market cap $39.20B). The key difference: Bristol-Myers Squibb Co is far larger — about 3.3× Coinbase Global, Inc.'s market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Coinbase Global, Inc. pays none. Which is the better fit depends on your goals.
| BMY | COIN | |
|---|---|---|
Market Cap | $129.94B | $39.20B |
Sector | Health | Technology |
52-Week High | $65.89 | $387.27 |
52-Week Low | $42.60 | $141.09 |
Enterprise Value | $163.92B | $36.85B |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
COIN trades at $150.35, up 1.12% with bearish technical signals but strong analyst support (55% buy ratings). The company reported mixed Q2 2026 results with revenue and EPS misses, though it achieved a record 10.3% global trading volume share. Fundamentals show revenue growth from $3.1B in 2023 to $7.2B in 2025, but profitability remains volatile with recent quarterly losses.
The stock faces near-term pressure from earnings misses and crypto market volatility, but long-term potential exists through business diversification beyond retail trading. Key risks include competitive threats and regulatory uncertainty, while the $207.20 consensus price target suggests 38% upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Coinbase Global, Inc.
Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →
